Senopsys and Patheon collaborate on palatable drug development
Senopsys LLC, a US-based specialty pharmaceutical services company, is to collaborate with drug development and manufacturing services provider, Patheon to accelerate the development of palatable drug products.
Senopsys LLC, a US-based specialty pharmaceutical services company, is to collaborate with drug development and manufacturing services provider, Patheon to accelerate the development of palatable drug products.
The deal means that Senopsys clients will have access to prototype drug formulations made by Patheon and Patheon will be able to offer its clients taste assessment and optimisation services.
Dr Shabbir Anik, Patheon's president of Global Pharmaceutical Development Services said: "We have a number of clients who are interested in developing palatable dosage forms to support pediatric regulatory requirements for investigational new drugs and life cycle management initiatives for approved drugs. We look forward to working with Senopsys to develop palatable products that meet the needs of diverse patient populations."
A drug product's aesthetics - aroma, flavor, texture, mouthfeel - can have a dramatic effect on patient compliance, health outcomes and product sales. Senopsys uses proprietary sensory assessment and formulation tools to develop palatable drug products. The company quantifies the taste masking challenge of drug substances, measures the palatability of prototypes and optimizes the sensory characteristics of drug products to meet the needs of diverse patient populations.
Patheon, which operates a network of 14 facilities in the US, Canada and Europe, offers a full range of formulation and analytical development, and clinical supplies manufacturing and process optimization capabilities. The company can quickly and cost-effectively manufacture small-scale batches of prototype drug formulations under GMP guidelines.